Relationships Between Köhne Category/Baseline Tumor Load and Early Tumor Shrinkage, Depth of Response, and Outcomes in Metastatic Colorectal Cancer.

dc.contributor.authorSartore-Bianchi, Andrea
dc.contributor.authorGarcía-Alfonso, Pilar
dc.contributor.authorGeissler, Michael
dc.contributor.authorKöhne, Claus-Henning
dc.contributor.authorPeeters, Marc
dc.contributor.authorPrice, Timothy
dc.contributor.authorValladares-Ayerbes, Manuel
dc.contributor.authorZhang, Ying
dc.contributor.authorBurdon, Peter
dc.contributor.authorTaieb, Julien
dc.contributor.authorModest, Dominik P
dc.date.accessioned2025-01-07T16:17:54Z
dc.date.available2025-01-07T16:17:54Z
dc.date.issued2021-05-25
dc.description.abstractIn metastatic colorectal cancer (mCRC), there are limited data on associations between early tumor shrinkage (ETS), depth of response (DpR), and patient characteristics. Data from patients with RAS wild-type mCRC who had participated in the PRIME (NCT00364013) and PEAK (NCT00819780) studies were analyzed retrospectively. ETS and DpR were assessed by baseline Köhne category/BRAF status (PRIME) and baseline tumor load (pooled PRIME and PEAK). Analysis populations included 436 to 665 patients. Patients' chances of achieving ETS of 30% or greater were 63.8%, 50.4%, and 41.9% in the low-, medium-, and high-risk Köhne categories, and 21.7% in those with BRAF mutations. Corresponding percentages for the highest DpR classification (71%-100%) were 47.7% (low risk), 23.6% (medium risk), 10.0% (high risk), and 4.2% (BRAF mutant). No clear relationship was observed between baseline tumor load and ETS or DpR. An ETS of 30% or greater and higher DpR values were associated with statistically significant prolongation of median progression-free survival and overall survival. Patients with mCRC categorized at baseline by the Köhne criteria as high risk or with BRAF mutations have lower chances of achieving an ETS of 30% or greater or a high DpR. Baseline tumor load was not predictive of ETS or DpR. Favorable ETS or DpR is associated with improved progression-free and overall survival.
dc.identifier.doi10.1016/j.clcc.2021.05.007
dc.identifier.essn1938-0674
dc.identifier.pmid34172397
dc.identifier.unpaywallURLhttps://air.unimi.it/bitstream/2434/865793/2/Sartore-Bianchi%20et%20al%20Clin%20Colorectal%20Cancer%202021.pdf
dc.identifier.urihttps://hdl.handle.net/10668/27739
dc.issue.number4
dc.journal.titleClinical colorectal cancer
dc.journal.titleabbreviationClin Colorectal Cancer
dc.language.isoen
dc.organizationSAS - Hospital Universitario Reina Sofía
dc.organizationInstituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)
dc.page.number305-313
dc.pubmedtypeJournal Article
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectOS
dc.subjectPFS
dc.subjectPanitumumab
dc.subjectRisk
dc.subjectVolume
dc.subjectmCRC
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshColorectal Neoplasms
dc.subject.meshHumans
dc.subject.meshRectal Neoplasms
dc.subject.meshRetrospective Studies
dc.subject.meshTumor Burden
dc.titleRelationships Between Köhne Category/Baseline Tumor Load and Early Tumor Shrinkage, Depth of Response, and Outcomes in Metastatic Colorectal Cancer.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number20

Files